Drug profile

The FDA adverse-event record for Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol

Name: Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

59 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol. Species, reactions, and outcomes follow.

#1020 of 2,679
by report volume (all drugs): 59
adverse-event reports: 86.4%
death-coded share: Cattle
most-reported species

Compiled by PlainBreed

Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol ranks #1017 of 2679 by total reports (59) and #14 of 1130 by death-coded share (86.4%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1): 97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1): #1017
This drug, reports of 2679: #14
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol has 59 reports now versus 59 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: −0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol changes

Signature read: Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol's 86.4% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

86.4%

Death-coded share of reports

Active Ingredients

Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol

Administration Routes

Subcutaneous

Species Affected

Cattle 59

Most Affected Breeds

Cattle (other) 40

Crossbred Bovine/Cattle 7

Aberdeen Angus 4

Holstein-Friesian also known as Holstein 2

Cattle (unknown) 2

Mixed (Cattle) 2

Cattle (unspecified) 1

Charolais 1

Most Reported Reactions

Lack of efficacy (bacteria) - NOS 52

Death 38

Lack of efficacy - NOS 10

CULTURE/TITER DATA ABNORMAL 9

Increased mortality rate 6

Abnormal test result 5

DEATH-TREATMENT FAILURE 4

Death by euthanasia 3

Lack of efficacy (protozoa) - Coccidia 3

PR-LUNG(S), LESION(S) 3

Fever 3

Pneumonia 2

Outcome Breakdown

Died

50 (47.2%)

Outcome Unknown

36 (34.0%)

Recovered/Normal

9 (8.5%)

Ongoing

7 (6.6%)

Euthanized

2 (1.9%)

Recovered with Sequela

2 (1.9%)

Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Nationwide drugs with similar profiles

Two openFDA-derived peer sets for Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar report volume

Nearest other drugs by FDA report count (59 here).

Buprenex 59 Gamithromycin 15% Solution For Injection 59 Heartworm Injection (Unknown) 59 Tulathromycin Inj Sol 59

Similar death-coded share

Nearest other drugs by death-coded share (86.4% here), distinct from the volume row.

Bov.Virus*3/M Haem/Past Mult 86.3% Bovine Virus*5/Past M+Mh Lv/Lb 86.9% Bovine Viral Diarrhea Virus, Type 2, Strain 53637, Lot Bvd2Mlv-D; Bovine Viral D 87.3% Bovine Respiratory Syncytial Virus, 597-10 10Th Psg Strain 375; Bovine Viral Dia 87.4%

What to do with this drug

Compare Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol's report volume and death-coded share against similar drugs nationwide. See similar drugs
Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol (#1020 of 2,679 by report volume); death-coded 86.4%. PlainBreed drug row · death-coded share stamp 86.4% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →